An interventional study of Software analysis and Ophthalmologist examination in Glaucoma, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.
Among the 43 studies in Glaucoma with a site in Spain, this one is the 4th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 39th registered.
1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:
Institut Catala de Retina · Sites in Spain
Ages 50–75
Clínica Rementería · Sites in Spain
Ages 18+
Fundacio Privada Mon Clinic Barcelona · Sites in Spain
Ages 18+
Barbara Burgos Blasco · Sites in Spain
Ages 18+
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Sites in Spain
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 4 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 61 across 965 interventional studies indexed under Glaucoma.
Median enrollment 100 across the 33 interventional studies, 365 across the 10 observational. Of the 32 that completed or were terminated, 8 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 43 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.
Hospital Clinic of Barcelona has 2 studies filed under Glaucoma — fewer than ten, so there is no comparison to draw.
1 of the studies in Glaucoma with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Two primary care-based screening systems will be tested to identify subjects with referrable glaucoma to hospital care.
Subjects between 45 to 64 years old living in the metropolitan area of Barcelona will be invited to participate in a one-time visit, with an optic disc examination and intraocular pressure (IOP).
The criteria for referring a patient will be the detection of glaucoma but with two different approaches depending on which Integrated Practice Unit (IPU) the patients will be allocated to: one arm using an Artificial Intelligence (AI) reading software of the optic disc picture; and the other one will base their referral after an ophthalmic examination performed by an ophthalmologist.
In both circuits, an optic nerve head photography will be obtained, and a masked reading center will be established to determine the ground truth for diagnosis.
This screening trial will explore the level of agreement between both systems and the cost-effectiveness of each of them.
Secondary analyses will include potential diagnostic composite scores (including other ancillary tests, such as optical coherence tomography images, that could maximize the screening process); the identification of population and disease characteristics (type of glaucoma, intraocular pressure) that could increase the effectivity and adherence to the screening process.
The purpose of this study is twofold: to validate in our population an Artificial Intelligence (AI) reading software of the optic disc picture, after comparing the estimated result (glaucoma/suspect/normal) to the ground truth; and to conduct a clinical trial where the level of agreement between both systems and the cost-effectiveness of each of them will be tested
In the first phase, a set of patients from our reference population will be selected. A standard-of-care ophthalmic examination with the usual ancillary tests to confirm or rule out the presence of glaucoma (including an optic disc retinography), will be performed. The patient (and the test) will be examined by a glaucoma specialist who will determine the status of the patient.
Then, the retinography will be analyzed by the AI software, providing the estimated result (glaucoma/suspect/normal). The level of agreement between the ground truth and the casted result will confirm the diagnostic accuracy.
In the second phase, a second set of patients will be recruited. In this case, the patients will be randomly allocated to either of the two arms of the study: In arm A the ancillary tests (including the retinography) will be performed, and the software will analyze the retinography, therefore providing the glaucoma status result. In arm B, the patients (and the test) will be examined by a glaucoma specialist who will then determine the status of the patient.
All the patients, irrespective of the diagnosis and the arm of the study will be then explored by another glaucoma specialist (reading center), who will be blinded to where the diagnosis comes from (AI software or glaucoma specialist), to the determine the level of agreement between the two screening systems
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In arm A, the visual acuity, refraction status and the ancillary tests will be performed. The obtained optic disc retinography will be analyzed by the AI software to determine whether the patient was a glaucomatous, suspect or healthy patient.
Diagnostic Test: Software analysis
In arm B, the visual acuity, refraction status and the ancillary tests will be performed, and then the patients (and the test) will be examined by a glaucoma specialist who will determine the status of the patient (glaucomatous, suspect or healthy).
Diagnostic Test: Ophthalmologist examination
The tested AI software analyzes the optic disc retinography to determine if the patient is healthy, a glaucoma suspect, or a glaucoma case
The ophthalmologist (a glaucoma specialist) will analyze the tests and will examine the patient to determine if the patient is healthy, a glaucoma suspect or a glaucoma case
Diagnostic agreement between the AI software and the ophthalmic examination
Level of agreement between the casted result by the AI software and the ophthalmic examination. This will be determined by the reading person (study chair)
Time frame: 18 months
Health-Related Quality of Life (HRQoL)
Health-Related Quality of Life (HRQoL) assessed by Euro Quality of Life -5 Dimensions (EQ-5D), for each arm of the clinical trial. It consists of a visual analog scale, ranging from 0 to 100 (0 being the worst imaginable health and 100 the best health the patient can imagine)
Time frame: 18 months
Demographics
Quantitative analysis of age, gender, ethnicity, and family history of glaucoma differences between the two arms
Time frame: 18 months
Intraocular pressure
Intraocular pressure values of glaucoma, suspects, and healthy patients of each arm of the study (in mmHg)
Time frame: 18 months
Optical coherence tomography (OCT)
OCT values of glaucoma, suspects, and healthy patients of each arm of the study (thickness reported in micrometers)
Time frame: 18 months
Visual field
Visual field defects (mean deviation, in decibels) of glaucoma, suspects, and healthy patients of each arm of the study
Time frame: 18 months
Cost-effective analysis of both screening methods
Cost-effective analysis will be conducted on each arm of the study comparing direct costs, and degree of visual impairment and comparing it to other screening programs (case-finding scenario) Mean costs and effects to estimate the Incremental Cost-Effectiveness Ratio (ICER, in euros, €) for artificial intelligence software screening versus ophthalmic examination will be compared
Time frame: 18 months
Risk score with parameters associated with positive screening of glaucoma
Analysis of the demographics (present or absent), ocular characteristics (present or absent), OCT values (in micrometers), and visual field values (in decibels) that could be associated with an increased likeliness of glaucoma diagnosis The degree of contribution of each parameter will be analyzed in a multivariate logistic regression, and then a risk score will be created using a scale from 1 to 100 (with being 1 the lowest value and 100 being the highest) to show how each parameter contributes to a "positive glaucoma diagnosis"
Time frame: 6 months
Plan to share: No — Individual Participant Data that could identify any patient will not be shared with other researchers. Patients will only be de-identified if a major health risk is detected, or under legal requirement by the competing authorities.
Started May 2024 (actual). Primary completion is estimated for Mar 2026, 22 months after the start.
Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 22 months is below that.
Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →